COMMUNIQUÉS West-GlobeNewswire

AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases
11/05/2026
Collaboration brings AGC Biologics’ advanced therapy expertise and global footprint to OTXL’s network, supporting a sustainable path from clinical development to commercial access for therapies serving the smallest [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA
11/05/2026
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY, JUNE 10, 2026, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be [...]
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA
11/05/2026
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY JUNE 10, 2026, AT 11:00 A.M. – Dear Shareholder, We have the honor of convening you to the Extraordinary General Meeting (the " EGM ") of [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2026 DE IBA SA
11/05/2026
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE ORDINAIRE 2026 DE IBA SA – MERCREDI 10 JUIN 2026, À 10H00 – Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée générale ordinaire (l’«  AGO  ») d’IBA, qui se [...]
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
11/05/2026
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to [...]
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
11/05/2026
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers MENLO PARK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- PacBio ( [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA
11/05/2026
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA – MERCREDI 10 JUIN 2026, À 11H00 – Cher Actionnaire, Nous avons l’honneur de vous convoquer à une Assemblée Générale Extraordinaire d’IBA (l’ « AGE » ) au [...]
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
11/05/2026
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM - [...]
Disc Medicine to Participate in Upcoming Investor Conferences
11/05/2026
WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
11/05/2026
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 [...]
CPTx appoints Edward Rebar as Chief Scientific Officer
11/05/2026
Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform David Maier appointed to expanded role as CPTx Chief Business Officer [...]
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
11/05/2026
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ” ), a clinical-stage biotech [...]
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
11/05/2026
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON CLEARWATER Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation [...]
MindBio Develops Fatigue Prediction Model using Speech Analytics and AI
11/05/2026
Patent application filed in World First claims. Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics. Early warning technologies for the detection of neurologically [...]
The Future of Intoxication Detection May Be in Your Voice
11/05/2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement [...]
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
11/05/2026
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions [...]
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
11/05/2026
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
11/05/2026
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to [...]

Pages